Activated immune cells secrete tiny capsules bearing DNA that can enter other immune and tumor cells to stimulate the body's ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Affinivax, Inc. (“Affinivax”), a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS™ (Multiple Antigen ...
AT-108 induces powerful, personalized anti-cancer responses by forcing tumor cells to present their antigens to the immune ...
In 2022 GSK acquired Boston-based Affinivax to scale a potentially disruptive vaccine technology, the Multiple Antigen Presenting System (MAPS), to help prevent infectious diseases. Watch to hear the ...
Secondary Finding Demonstrates Tattooing Skin with Tolerogenic Genes AIRE or FoxP3 “Balances” Immune System to Stop Autoimmunity ELK CITY, Idaho--(BUSINESS WIRE)-- Therapeutic Solutions International ...
GSK has agreed to buy the vaccine developer Affinivax for $2.1 billion, plus up to $1.2 billion in milestone payments. Affinivax, based in Cambridge, Massachusetts, uses its Multiple Antigen ...
ERAPs (ERAP1 and ERAP2) are emerging therapeutic targets associated with multiple autoimmune diseases.Genomics will assemble the largest available genetic resource to evaluate how ERAP variants ...
Genomics, a science-led techbio company using large-scale genetic information to accelerate drug discovery and development and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results